2. Apoptosis
  3. Apoptosis MDM-2/p53 Caspase
  4. Anticancer agent 311

Anticancer agent 311 is an apoptosis inducer and p53 modulator. Anticancer agent 311 increases p53 levels, activates cleaved caspase-3, reduces p-Cdc25C levels, and disrupts p-p44/42 MAPK phosphorylation. Anticancer agent 311 induces G2/M phase arrest, inhibits cancer cell viability in a concentration- and time-dependent manner, and exhibits low toxicity to non-cancer cells. Anticancer agent 311 prevents tumor growth and angiogenesis in mouse xenograft models without detectable toxicity. Anticancer agent 311 can be used for the research of lung cancer.

For research use only. We do not sell to patients.

Anticancer agent 311

Anticancer agent 311 Chemical Structure

CAS No. : 421579-95-5

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anticancer agent 311 Related Antibodies

Top Publications Citing Use of Products

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anticancer agent 311 is an apoptosis inducer and p53 modulator. Anticancer agent 311 increases p53 levels, activates cleaved caspase-3, reduces p-Cdc25C levels, and disrupts p-p44/42 MAPK phosphorylation. Anticancer agent 311 induces G2/M phase arrest, inhibits cancer cell viability in a concentration- and time-dependent manner, and exhibits low toxicity to non-cancer cells. Anticancer agent 311 prevents tumor growth and angiogenesis in mouse xenograft models without detectable toxicity. Anticancer agent 311 can be used for the research of lung cancer[1].

IC50 & Target

Caspase-3

 

In Vitro

Anticancer agent 311 (#2714) (48 h) potently inhibits the viability of murine Lewis lung carcinoma LL/2 cells with an IC50 of 5.43 μM and mouse mammary carcinoma 4T1 cells with an IC50 of 6.12 μM, while showing minimal toxicity to non-cancer NIH-3T3 and HK-2 cells (IC50 >40 μM)[1].
Anticancer agent 311 (4-20 μM; 24-72 h) inhibited LL/2 cell viability in a time- and concentration-dependent manner[1].
Anticancer agent 311 (5-20 μM; 48 h) induces G2/M phase arrest in murine Lewis lung carcinoma LL/2 cells, with 77.7% of cells accumulating in G2/M after treatment with 20 μM for 48 h[1].
Anticancer agent 311 (5-20 μM; 48 h) induces apoptosis in murine Lewis lung carcinoma LL/2 cells in a concentration-dependent manner, reaching 50.2% at 20 μM after 48 h, and disrupts mitochondrial membrane potential in these cells[1].
Anticancer agent 311 (2.5-10 μM; 24 h) downregulates p-Cdc25C, p-p44/42 MAPK, and p-Akt while upregulating p53 and cleaved caspase-3 in murine Lewis lung carcinoma LL/2 cells after 24 h of treatment, supporting G2/M phase arrest and caspase-dependent apoptosis[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anticancer agent 311 Related Antibodies

Cell Viability Assay[1]

Cell Line: Lewis lung carcinoma LL/2 cells
Concentration: 4 μM; 8 μM; 12 μM; 16 μM; 20 μM;
Incubation Time: 24 h; 48 h; 72 h
Result: Inhibited LL/2 cell viability in a time- and concentration-dependent manner.

Cell Cycle Analysis[1]

Cell Line: Lewis lung carcinoma LL/2 cells
Concentration: 5 μM; 10 μM; 20 μM
Incubation Time: 48 h
Result: Increased the percentage of LL/2 cells in the G2/M phase to 77.7% at 20 μM, accompanied by decreases in the G0/G1 and S phases.

Apoptosis Analysis[1]

Cell Line: Lewis lung carcinoma LL/2 cells
Concentration: 5 μM, 10 μM, 20 μM
Incubation Time: 48 h
Result: Increased the apoptosis rate of LL/2 cells to 22.9% with 5 μM, 45.1% with 10 μM, and 50.2% with 20 μM after 48 h.
Caused a concentration-dependent decrease in Rho 123 fluorescence, indicating collapse of mitochondrial membrane potential (ΔΨm).

Western Blot Analysis[1]

Cell Line: Lewis lung carcinoma LL/2 cells
Concentration: 2.5 μM, 5 μM, 10 μM
Incubation Time: 24 h
Result: Downregulated the expression of phosphorylated Cdc25C (p-Cdc25C), phosphorylated p44/42 MAPK (p-p44/42 MAPK), and phosphorylated Akt (p-Akt) in a concentration-dependent manner.
Upregulated the expression of p53 and cleaved caspase-3 in a concentration-dependent manner.
In Vivo

Anticancer agent 311 (#2714) (25-100 mg/kg; i.p.; daily; 14 days) is well-tolerated in healthy C57BL/6 mice at doses up to 100 mg/kg daily for 14 days, with no detectable toxicity[1].
Anticancer agent 311 (#2714) (25-100 mg/kg; i.p.; daily; 28 days) exhibits potent anti-lung cancer efficacy in C57BL/6 mice, achieving up to 58.1% tumor growth inhibition at 100 mg/kg, while also increasing survival, reducing angiogenesis, and inducing tumor cell apoptosis with no detectable toxicity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (male and female, 18-22 g)[1]
Dosage: 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: i.p.; daily; 14 days
Result: Caused no mortality, adverse clinical signs, or obvious pathological damage in any treated group.
Showed no significant differences in hematological parameters (WBC, RBC, HGB, HCT, PLT) between treated groups and vehicle control.
Showed no significant differences in serum biochemical parameters (HDL, TG, CHOL, CREA, BUN, GLU, ALP, ALB, TP, AST, ALT) between treated groups and vehicle control.
Animal Model: C57BL/6 (female, 6-8 weeks old, 18-22 g, subcutaneous implantation of LL/2 murine Lewis lung carcinoma cells)[1]
Dosage: 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: i.p.; daily; 28 days
Result: Achieved 45.1% tumor growth inhibition at 50 mg/kg compared to vehicle control.
Achieved 58.1% tumor growth inhibition at 100 mg/kg compared to vehicle control.
Significantly increased mouse survival compared to vehicle control across all doses.
Reduced CD31 staining by 37.4% in tumor tissues compared to vehicle control.
Reduced CD105 staining by 15.2% in tumor tissues compared to vehicle control.
Increased apoptotic tumor cells 11-fold compared to vehicle control.
Caused no significant changes in body weight during treatment.
Molecular Weight

439.46

Formula

C23H18FNO5S
CAS No.
SMILES

O=C(C1=C(C2=CC=CC=C2)OC3=C1C=C(NS(=O)(C4=CC=C(C=C4)F)=O)C=C3)OCC
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anticancer agent 311 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anticancer agent 311421579-95-5Anticancer agent311Anticancer agent-311ApoptosisMDM-2/p53Caspasemurine Lewis lung carcinoma LL/2 cellsmouse mammary carcinoma 4T1 cellsNIH-3T3 cellsHK-2 cellsp-Cdc25Cp-p44/42 MAPKp53G2/M phase arrestapoptosiscleaved caspase-3Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anticancer agent 311
Cat. No.:
HY-182382
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.